Evidence map›Paper›PMID 40861454›Full record

ArticleFrontiers in immunology2025

Impact of viral load kinetics and recurrent cytomegalovirus infection in kidney transplantation.

Sabina Dobrer, Karen R Sherwood, Kimberly Davis, James H Lan, John Gill, Nancy Matic, Paul A Keown

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sabina DobrerDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Karen R SherwoodDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Kimberly DavisGlobal Evidence & Outcomes Within R&D, Takeda Development Center Americas, Inc., Lexington, MA, United States.
James H LanDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
John GillDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
Nancy MaticDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Paul A KeownDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: We have shown that viral load kinetics during the first cytomegalovirus (CMV) viremic episode are important predictors of kidney transplant failure. This article evaluates the incremental hazard of recurrent CMV viremia and of viral load kinetics on graft and patient survival. Methods: This retrospective cohort study included 2,464 sequential kidney transplants performed between 2008 and 2018. Care was delivered according to a uniform provincial protocol, and patients were followed for up to 13 years with standardized therapy and continuous monitoring of clinical course, CMV infection, viral load kinetics, and graft and patient outcomes. Results: 434/2,464 (17.6%) patients (age range: 2-80 years) developed CMV infection, of whom 67/434 (15.4%) had 150 episodes of recurrent infection. Mean cumulative CMV frequency reached an asymptote of 21% at 500 days, with the highest rate (43%) in D+/R-, and lowest (1%) in D-/R- risk groups. Multinomial adjusted regression described a composite risk phenotype that included increased age, non-Caucasian race, diabetes, D+/R- status, and delayed graft function ( Conclusions: Patients with a recurrent CMV viremia post-transplant are at exceptionally high risk of transplant failure as measured by graft loss or death, which is determined by both composite risk phenotype and CMV viral load kinetics. Conventional prophylaxis appears to be inadequate to protect these patients from recurrent infection and its serious consequences, and alternative treatment strategies, with continuous long-term monitoring and rapid, effective therapy, are vital to maximize transplant success.

Indexed as

CytomegalovirusCytomegalovirus InfectionsKidney TransplantationViral LoadAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleGraft RejectionGraft SurvivalHumansMaleMiddle Agedclinical outcomesCMVcytomegaloviruskidney transplantrecurrent infectionviral load kinetics

Identifiers

PMID40861454
PMCPMC12371426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.